A 2007 paper compared 17-AAG and bortezomib effects on myeloma cells and found that both drugs produced upregulation of grp78, gp96, and CHOP, all of which are downstream effects of PERK activation (Davenport et al., 2007). The gene discussed is EIF2AK3; the disease is plasma cell myeloma.